The European Patent Office (EPO) has published patent application EP2026030253A1, related to Human Papillomavirus (HPV) vaccines. The publication date is March 18, 2026. The application details inventors and includes International Patent Classification (IPC) codes such as A61K 39/12, A61P 31/20, C07K 14/005, C12N 15/86, and A61K 39/00, covering aspects of vaccines, viral diseases, and genetic engineering.

This publication signifies the formal disclosure of the patent application. While it does not impose immediate compliance obligations on regulated entities, it is a key step in the patent process. Companies involved in pharmaceutical research and development, particularly in the vaccine sector, should note this publication for intellectual property landscape monitoring. The designation of inventors has not yet been filed, and the application is designated for numerous European states.